Ribociclib Eligible Advanced Or Metastatic Breast Cancer Therapeutics
1. Kisqali patent expiration
Treatment: In combination with fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy in postmenopausal women or in men, for the treatment of hr-positive, her2-negat...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9193732 | NOVARTIS | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Nov, 2031
(5 years from now) | |
| US8415355 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Mar, 2031
(4 years from now) | |
| US8685980 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
May, 2030
(3 years from now) | |
| US8324225 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Jun, 2028
(1 year, 11 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9868739 | NOVARTIS | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Nov, 2031
(5 years from now) | |
| US9416136 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Aug, 2029
(3 years from now) | |
| US8962630 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Dec, 2029
(3 years from now) | |
| US12064434 | NOVARTIS | Ribociclib tablet |
Apr, 2036
(9 years from now) | |
| US10799506 | NOVARTIS | Ribociclib tablet |
Apr, 2036
(9 years from now) | |
| US12419894 | NOVARTIS | Ribociclib Tablet |
Apr, 2036
(9 years from now) | |
|
US12544380 (Pediatric) | NOVARTIS | Combination Therapy Using Ribociclib And An Aromatase Inhibitor For The Treatment Of Hr+ Breast Cancer |
Feb, 2035
(8 years from now) | |
|
US8685980 (Pediatric) | NOVARTIS | Pyrrolopyrimidine Compounds And Their Uses |
Nov, 2030
(4 years from now) | |
|
US8324225 (Pediatric) | NOVARTIS | Pyrrolopyrimidine Compounds And Their Uses |
Dec, 2028
(2 years from now) | |
| US12544380 | NOVARTIS | Combination Therapy Using Ribociclib And An Aromatase Inhibitor For The Treatment Of Hr+ Breast Cancer |
Aug, 2034
(8 years from now) | |
|
US8415355 (Pediatric) | NOVARTIS | Pyrrolopyrimidine Compounds And Their Uses |
Sep, 2031
(5 years from now) | |
|
US9193732 (Pediatric) | NOVARTIS | Salt(S) Of 7-Cyclopentyl-2-(5-Piperazin-1-Yl-Pyridin-2-Ylamino)-7H-Pyrrolo[2,3-D]Pyrimidine-6-Carboxylic Acid Dimethylamide And Processes Of Making Thereof |
May, 2032
(5 years from now) | |
|
US12419894 (Pediatric) | NOVARTIS | Ribociclib Tablet |
Oct, 2036
(10 years from now) | |
|
US8962630 (Pediatric) | NOVARTIS | Pyrrolopyrimidine Compounds And Their Uses |
Jun, 2030
(3 years from now) | |
|
US12544379 (Pediatric) | NOVARTIS | Combination Therapy Using Ribociclib And Fulvestrant For The Treatment Of Hr+ Breast Cancer |
Feb, 2035
(8 years from now) | |
|
US12064434 (Pediatric) | NOVARTIS | Ribociclib Tablet |
Oct, 2036
(10 years from now) | |
| US12544379 | NOVARTIS | Combination Therapy Using Ribociclib And Fulvestrant For The Treatment Of Hr+ Breast Cancer |
Aug, 2034
(8 years from now) | |
|
US9416136 (Pediatric) | NOVARTIS | Pyrrolopyrimidine Compounds And Their Uses |
Feb, 2030
(3 years from now) | |
|
US9868739 (Pediatric) | NOVARTIS | Salt(S) Of 7-Cyclopentyl-2-(5-Piperazin-1-Yl-Pyridin-2-Ylamino)-7H-Pyrrolo[2,3-D]Pyrimidine-6-Carboxylic Acid Dimethylamide And Processes Of Making Thereof |
May, 2032
(5 years from now) | |
|
US10799506 (Pediatric) | NOVARTIS | Ribociclib Tablet |
Oct, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-783) | Jul 18, 2021 |
| New Indication(I-784) | Jul 18, 2021 |
| New Chemical Entity Exclusivity(NCE) | Mar 13, 2022 |
| New Patient Population(NPP) | Dec 10, 2024 |
| New Indication(I-950) | Sep 17, 2027 |
| Pediatric Exclusivity(PED) | Mar 17, 2028 |
Drugs and Companies using RIBOCICLIB SUCCINATE ingredient
NCE-1 date: 13 March, 2021
Market Authorisation Date: 13 March, 2017
Dosage: TABLET
How can I launch a generic of KISQALI before its drug patent expiration?
More Information on Dosage
KISQALI family patents
